Barclays on U.S. Specialty Pharmaceuticals: Muddling Now, but Opportunity Remains
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Price: $15.86 --0%
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays on U.S. Specialty Pharmaceuticals: Muddling Now, but Opportunity Remains
Analyst, Douglas D. Tsao, said, "We continue to see long-term opportunity for the major generics makers in Europe, notably Mylan (NYSE: MYL), TEVA (Nasdaq: TEVA) & Watson (NYSE: WPI) post-Actavis closing, and, perhaps most importantly, early evidence that competitive dynamics are breaking in their favor, despite continued near-term headwinds which are forcing them to muddle through."
Tsao notes that despite investor controversy, Europe offers opportunities for MYL and TEVA, considering recent acquisitions in those markets by these companies. WPI is playing catch up. He also noted that 80% of all U.S. prescriptions are generic and 50% throughout Europe.
As far as pricing goes, Tsao does note the concern that there will be additional price cuts in certain markets, but it looks like the worst is now behind us. And, even though investors are split, Barclays is in the camp that feels Europe represents a long-term opportunity.
Analyst, Douglas D. Tsao, said, "We continue to see long-term opportunity for the major generics makers in Europe, notably Mylan (NYSE: MYL), TEVA (Nasdaq: TEVA) & Watson (NYSE: WPI) post-Actavis closing, and, perhaps most importantly, early evidence that competitive dynamics are breaking in their favor, despite continued near-term headwinds which are forcing them to muddle through."
Tsao notes that despite investor controversy, Europe offers opportunities for MYL and TEVA, considering recent acquisitions in those markets by these companies. WPI is playing catch up. He also noted that 80% of all U.S. prescriptions are generic and 50% throughout Europe.
As far as pricing goes, Tsao does note the concern that there will be additional price cuts in certain markets, but it looks like the worst is now behind us. And, even though investors are split, Barclays is in the camp that feels Europe represents a long-term opportunity.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
Create E-mail Alert Related Categories
Analyst Comments, Retail SalesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
